Answers are grounded in this paper and cite their sources.
Three articles in this issue of the Journal report on the therapeutic potential of a new kid on the kinase inhibitor block: crizotinib, an ATP-competitive inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.Kwak et al.1 summarize a study involving patients with non–small-cell lung cancer who were enrolled in a phase 1 trial, starting in 2008, hot on the heels of a study in which cell lines derived from non–small-cell lung tumors were shown to be sensitive to NVP-TAE6842 and crizotinib (PF-02341066).3,4 From a cohort of 1500 patients with non–small-cell lung cancer, 82 (5.5%) were found to . . .
No takes yet. Share an insight, caveat, or question.
Hallberg et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: